Must the start of insulin treatment in type 2 diabetes be connected with increasing of their body weight?
Abstract
BACKGROUND AND AIMS: The primary objective of the observational study was to evaluate the change in body weight and BMI during 12 months of insulin detemir treatment and to compare it with the changes in body weight and BMI during the previous 12 months of another basal insulin (NPH, glargin) treatment. Treatment with Short acting insulins were adjusted by physicians according to the standard of care.
The secondary objective of the study was to evaluate the changes in glycaemic control measured by HbA1c and fasting glycemia blood glucose after 6 and 12 months of the treatment with insulin detemir and compare it with the retrospective period. MATERIALS AND METHODS: This study was a 17-sites, open, not controlled, observational.
Data of 206 patients with type 2 diabetes were collected, these patients were treated with basal insulin at least 12 month before starting with insulin detemir. Starting insulin detemir was at the solely discretion of the individual physician based on clinical judgement.
The basic data of patients were recorded at the beginning of the study: year of birth age, gender, year of onset diagnosis diabetes mellitus and duration of insulinotherapy. Besides this Following data: weight, type of insulin therapy +- OAD therapy, rate of hypoglycaemic events and HbA1c values: 12 and 6 month before switch to insulin detemir and approximately 3,6,9 and 12 month after starting insulin detemir therapy were recorded.
CONCLUSION: The weight of patients increased on the average by 1.94 kg before change of basal therapy in one year. Weight decreased by 1,5 kg per year on the average after switch to detemir.
Mean drop in HbA1c value was -0.49% and fasting blood glucose value -1.33 mmol/l.